Due to the importance of treatment of gestational diabetes, the research will be conducted to assess the effect of maternal and neonatal outcomes in gestational diabetes treated with glibenclamide. 278 pregnant women with singleton pregnancies and no history of diabetes, at 33 -11 weeks of gestation will be enrolled and randomly assigned to two groups and 139 eligible women in any glibenclamide and insulin groups. Exclusion criteria included cardiovascular disease, hematological disease, renal or liver disease, severe infectious disease, acute respiratory failure and premature rupture of membrane. Patients will take glibenclamide or routine treatment (insulin) to level of fasting blood glucose and two hours after meals reach less than 90 and 120 respectively. After sampling, fetal Apgar at 1 and 5 minutes, percentile of newborn birth weight, blood sugar three hours after birth, calcium, incidence of hyperbilirubinemia, macrosomia, intrauterine growth restriction, shoulder dystocia, perinatal mortality and morbidity, respiratory distress, need to be admitted to the neonatal intensive care unit in new born, preeclampsia, birth trauma and hypoglycaemia in women will be compared in insulin and glibenclamide intervention group by statistical analysis techniques.